Amarin Co. plc (AMRN) Insider Steven B. Ketchum Sells 135,205 Shares

Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 135,205 shares of Amarin stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $4.41, for a total value of $596,254.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Amarin Co. plc (AMRN) traded up $0.40 during midday trading on Tuesday, hitting $4.44. The company had a trading volume of 12,801,029 shares, compared to its average volume of 2,245,653. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63. Amarin Co. plc has a 12 month low of $2.81 and a 12 month high of $4.60. The firm has a market cap of $1,200.00, a P/E ratio of -16.44 and a beta of 0.62.

Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. During the same period last year, the business earned ($0.08) EPS. The company’s revenue was up 45.4% compared to the same quarter last year. equities research analysts anticipate that Amarin Co. plc will post -0.22 EPS for the current year.

Several equities analysts have recently issued reports on AMRN shares. Cantor Fitzgerald set a $10.00 price target on Amarin and gave the company a “buy” rating in a research note on Thursday, January 4th. ValuEngine downgraded Amarin from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Zacks Investment Research downgraded Amarin from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Amarin in a report on Thursday, November 2nd. Finally, BidaskClub downgraded Amarin from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Amarin has a consensus rating of “Buy” and an average price target of $7.75.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. boosted its holdings in shares of Amarin by 1.1% during the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 300 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Amarin by 15.2% during the 2nd quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 5,000 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Amarin during the 3rd quarter valued at $226,000. Stevens Capital Management LP acquired a new position in Amarin during the 3rd quarter worth about $229,000. Finally, Stonepine Capital Management LLC acquired a new position in Amarin during the 2nd quarter worth about $302,000. 40.14% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Amarin Co. plc (AMRN) Insider Steven B. Ketchum Sells 135,205 Shares” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/23/amarin-co-plc-amrn-insider-steven-b-ketchum-sells-135205-shares.html.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply